We investigated efficacy and safety of rabbit anti-thymocyte globulin (rATG), cyclosporine and granulocyte colony-stimulating factor (G-CSF) as first-line therapy for patients with aplastic anemia (AA) and low or intermediate-1 or hypoplastic myelodysplastic syndrome (MDS). rATG 3.5 mg/kg (or 2.5 mg/kg per day for patients X55 years with MDS) was given for 5 days. Cyclosporine (5 mg/kg) and G-CSF (5 lg/kg) were given daily and continued for up to 6 months or longer. Responses were assessed about 3 and 6 months after therapy. Thirty-six patients have been enrolled on study and 32 patients treated; 25 were evaluable for a response (13 with AA, 12 with MDS); the rest are too early. The median age was 62 years (range, 20-83) for patients with AA and 63 (range, 42-80) for patients with MDS. Of 13 patients, 12 (92%) patients with AA responded (5 complete response (CR), 7 partial response (PR)), whereas of 12 patients, 4 (33%) patients with MDS responded (1 CR, 3 PR). For patients with AA, the median time to response (TTR) was 93 days (range, 79-623), whereas in the MDS group the median TTR was 111 days (range, 77-139). Grade III/IV toxicities were mainly cytopenias and neutropenic fever. Combination of rATG, cyclosporine and G-CSF is safe and effective as first-line treatment of AA and has significant activity in low-risk MDS.
Introduction
A spectrum of bone marrow failure disorders, including paroxysmal nocturnal hemoglobinuria (PNH), pure red cell aplasia, aplastic anemia (AA) and myelodysplastic syndrome (MDS), overlap and share some underlying pathogenic mechanisms, 1 causing occasional difficulty in delineating differences between them. This especially holds true for the distinction between AA and hypocellular MDS. 2, 3 There are several lines of evidence suggesting that these disorders may result from the immune-mediated destruction of hematopoietic cells by autoreactive T lymphocytes 2, 4 with production of inhibitory soluble factors such as interferon-g and tumor necrosis factor-a. 1 Immunophenotyping of T cells suggests the presence of pathogenic clones involved in this immune-mediated process. 1, 5 Characterization of the T-cell-receptor Vb chain of the activated lymphocytes has shown that the immune response is clonal and may be antigen specific. 5 These findings are corroborated by the clinical utility of immunosuppressive treatment (IST) in treating a number of these disorders. 6 Furthermore, there is a strong association with clonal stem cell disorders such as PNH. 7 In one study of 115 patients with AA, a glycosylphosphatidyl-anchored protein-deficient clone was identified in 25 (22%) patients. 8 Traditionally, patients with severe AA are treated with equine anti-thymocyte globulin (hATG) and cyclosporine (CsA). Adding CsA to hATG leads to a response rate of 70% at 3 months and a 5-year survival rate of around 90%. 9, 10 Many patients do not have an optimal response to a single course of hATG and others become CsA dependent with a decrease in blood counts when CsA is discontinued. 6 Upon relapse, a second course of hATG can be given, but retreatment from the same source can lead to allergic reactions. Tichelli et al. 11 reported an increased rate of immediate hypersensitivity reactions after retreatment with hATG (11 vs 2%, P ¼ 0.05).
MDS represents clonal stem cell disorders typically affecting older adults and characterized by a dysplastic bone marrow and ineffective hematopoiesis. 12 Some patients with MDS can be successfully treated with IST. 13 However, response to IST occurs less commonly in patients with MDS with a rate of about 25%. These disorders can be potentially distinguished by the presence of normal cytogenetics in patients with AA as opposed to cytogenetic abnormalities in patients with MDS.
14 Rabbit anti-thymocyte globulin (rATG) has been used successfully in combination with CsA and granulocyte colonystimulating factor (G-CSF) to treat patients with AA who have relapsed from therapy with hATG. 15 ATG can be effective in the treatment of AA and MDS through its multifaceted immunomodulatory mechanisms. In vitro studies have shown that it has a variety of effects on the immune system including: (1) T-cell depletion in blood and peripheral lymphoid tissue through complement-dependent lysis and T-cell activation, (2) modulation of cell-surface molecules involved in leukocyte-endothelium interaction, (3) induction of apoptosis in B-cell lineages, (4) interference with dendritic cells and (5) the induction of regulatory T and natural killer T cells. 16 No prior studies of rATG in first-line therapy of AA have been conducted. In this study, we evaluate the efficacy and safety of rATG, CsA, G-CSF and methylprednisolone in patients with AA as well as patients with hypoplastic and low-risk MDS.
Materials and methods

Patients
This study was approved by our institutional review board. Patients had to have severe AA or hypoplastic MDS with a bone marrow cellularity o30% and with at least two of three peripheral counts decreased with absolute neutrophil count (ANC) o0.5 Â 10 9 per liter, platelet count o20 Â 10 9 per liter and/or hemoglobin (Hb) o8.0 g/100 ml. After eight patients were enrolled, the study was amended to include patients with MDS who had a bone marrow cellularity 430% and low or intermediate-1 risk by the IPSS (International Prognostic Scoring System) and required treatment (that is, transfusion dependent). All patients had to be 15 years of age or older and have adequate renal and hepatic function. No investigational therapy could have been given 14 days before enrollment. Patients were excluded if they had active infections or were HIV positive, were pregnant or breast-feeding or had active and uncontrolled medical illnesses. Patients with AA should not have received any prior therapy. Patients with MDS could have received prior therapy with biological agents or growth factors.
Treatment regimen
Patients with AA received rATG 3.5 mg/kg per day for 5 days whereas those with MDS received rATG 3.5 mg/kg per day for 5 days (or 2.5 mg/kg per day if X55 years of age). Methylprednisolone 1 mg/kg per day i.v. was given before each thymoglobulin dose with a subsequent oral prednisone taper over 3 weeks. In addition to methylprednisolone, acetaminophen 650 mg, diphenhydramine 25 mg i.v. and meperidine 25 mg i.v. were given 30 min before rATG to limit the incidence of infusion-related toxicities. Meperidine 25 mg i.v. could also be given every 3 h as needed for chills/rigors during infusion. Furthermore, hydrocortisone 50-100 mg i.v. could be added if necessary. All the premedications could be given again if there was a reaction to the initial infusion. CsA 5 mg/kg orally was given for 6 months or longer and was started after the completion of thymoglobulin with levels maintained between 200 and 400 ng/ml. G-CSF 5 mg/kg was given subcutaneously daily for up to 3 months starting after completion of thymoglobulin. All patients received prophylactic broad-spectrum antimicrobials with levofloxacin, fluconazole and valacyclovir (or acceptable alternatives). During rATG administration, patients were transfused with platelets if they had a platelet count p10 Â 10 9 or 410 Â 10 9 per liter with evidence of clinical bleeding.
Evaluation during the course of therapy included complete blood count with platelets, creatinine, liver function tests and CsA levels. Bone marrow aspiration/biopsy was carried out at 3 months and repeated later in some cases to assess response.
Assessment of response and toxicity
The primary end point was to assess efficacy of the combination of rATG, methylprednisolone, CsA and G-CSF in achieving response (complete response (CR), partial response (PR) and hematologic improvement (HI)) in treating patients with severe AA or MDS and assessing the treatment effect on overall survival. The secondary end point was to assess the safety of the regimen.
Responses were evaluated around 3 months after the administration of therapy and again at 6 months if necessary. For AA, CR was defined as the normalization of the peripheral blood, a bone marrow with p5% bone marrow blasts with normal cell lines, a peripheral blood granulocyte count X1.0 Â 10 9 per liter, HbX10 g/100 ml and platelet count X100 Â 10 9 per liter. PR was defined by transfusion independence with a peripheral blood granulocyte count X0.5 Â 10 9 per liter, a platelet count X20 Â 10 9 per liter and HbX8.0 g/100 ml, with the above values lasting at least 8 weeks. For MDS, the international standardized criteria for response was used. 17 
Statistical analysis
The primary outcome was overall response (CR, PR or HI). The Bayesian sequential monitoring method was used to assess efficacy and safety monitoring. [18] [19] [20] Patients with severe AA and patients with MDS were evaluated separately. Survival and time to progression for the entire cohort and response duration was evaluated using the Kaplan-Meier method with pointwise confidence intervals based on the variance formula of Greenwood. Within-patient differences before and after treatment were evaluated by using the paired t-test for continuous variables and permutation tests for categorical variables. Prognostic factors for response were assessed by using logistic regression models and the Cox proportional hazard models. The effect of response on survival and disease progression was analyzed by modeling response as a time-varying covariate in the Cox model.
Results
A total of 36 patients were enrolled on study with 3 patients choosing alternative therapies after enrollment on the study and 1 patient dying before administration of treatment. Among the 32 patients treated (17 with AA, 15 with MDS), 4 have been on study for less than 2 months, 1 was lost to follow-up and 2 died early in the course of treatment from bleeding or infectionrelated complications; therefore, 13 patients with AA and 12 with MDS were evaluable for a response. Patient characteristics are shown in Table 1 .
Seven of 17 (41%) patients with AA were human leukocyte antigen (HLA)-DR-15 þ compared to 6 of 15 (40%) patients with MDS. Six of the seven patients with AA who were HLA-DR15 þ were evaluable for a response as one patient was too early on treatment. Five of these six patients responded (83%) (three CR, two PR), whereas one of the six patients with MDS who had HLA-DR15 þ responded (17%) (PR). There was no statistical difference in response among patients who were or were not HLA-DR15 þ . For the patients tested, 1 of 10 patients with AA and 0 of 11 patients with MDS had a detectable PNH clone. The paucity of patients with PNH þ impedes interpretation of the difference in response due to the presence or absence of the PNH clone. Abbreviations: AA, aplastic anemia; ANC, absolute neutrophil count; Hb, hemoglobin; HLA-DR15+, human leukocyte antigen; MDS, myelodysplastic syndrome; PNH+, paroxysmal nocturnal hemoglobinuria clone.
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Sixteen of 17 patients (94%) with AA and 9 of 15 patients (60%) with MDS had diploid cytogenetics (Tables 2 and 3) .
Thirteen patients with AA were evaluable for response as one patient was lost to follow-up and three were too early in the treatment course. Twelve patients with MDS were evaluable for response as two died on treatment before response assessment and one was too early in treatment. Twelve of 13 (92%) patients with AA responded (5 CR, 7 PR). Of the 12 patients with MDS, 4 (33%) responded (1 CR, 3 PR). Eight patients with MDS (66%) had no response and two patients died (17%) while on treatment. The outcome data, response and grade III and IV toxicities for each respective patient are shown in Tables 2 and 3 . Patients with AA had higher overall response rate 12 vs 4 compared to patients with MDS ( Table 4) .
The median time to response (TTR) for patients with AA was 93 days (range, 79-623). The patient who had a TTR of 623 days had a PR at day 92, but a CR occurred at day 623 when the platelet count was 105. In the MDS group, the median TTR was 111 days (range, 77-139). The median response duration for both groups has not been reached. Side effects were recorded for 30 of 32 patients on treatment. The main grade III/IV toxicities included thrombocytopenia in 20 patients (67%), anemia in 8 (27%), leukopenia in 17 (57%) and neutropenic fever in 4 (13%). Other grade III/IV toxicities include renal failure, hypertension, pneumonia, urinary tract infection, fever, increased liver function tests, hyperglycemia and syncope (1 patient each). The deaths in the MDS group were due to gastrointestinal bleeding (GIB) and septicemia ( Table 5 ). The patient who died from GIB presented to the hospital with lightheadedness and was found to have a Hb of 7.1 g/100 ml and a platelet count of 45 Â 10 9 per liter. This patient had gross bleeding from both the upper and lower gastrointestinal tract that was refractory to both protonix and amicar drips. Endoscopic intervention was not possible and the patient did not respond to resuscitation efforts. The second patient died from septicemia; this patient had presented with confusion and delirium and was diagnosed with a urinary tract infection (coagulase-negative staphylococcus) and acute right facial sinusitis. Despite treatment with antibiotics and some initial clinical improvement, the patient died from sepsis-related events.
With a median follow-up of 12.2 months (range, 0.4-37.3), 16 of the 17 (94%) patients with AA remain alive with 1 patient lost to follow-up. With a median follow-up of 12.4 months (range, 1.0-28), 9 of 15 patients with MDS remain alive (60%) and 6 have died. The probability of response duration is seen in Figure 1 ; two of the patients with AA and none of the patients with MDS who responded have relapsed.
Discussion
Immunosuppression with equine ATG and CsA is the standard treatment for patients with AA who are not candidates for stem cell transplantation. Several studies have used equine ATG for hypoplastic MDS with promising results.
Several predictors of a possible higher response to IST have been reported including HLA-DR15 expression and the Immunosuppressive therapy for bone marrow failure R Garg et al presence of PNH cells. 21 rATG has largely been reserved for treating patients with AA who have relapsed after therapy with hATG. To date, no studies of rATG as first-line therapy for AA has been conducted.
The efficacy of equine ATG in AA has been well established. Rosenfeld et al. 10 treated 55 patients with AA with hATG and CsA; 67% had a response by 3 months and 78% a response by 1 year. Frickhofen et al. 6 reported their 11-year experience with equine ATG with or without CsA. The response rate was 70% with CsA vs 41% without it (P ¼ 0.015). Patients responded more rapidly with the addition of CsA (median, 60 vs 82 days; P ¼ 0.019) and had a more favorable failure-free survival (39 vs 24%; P ¼ 0.04), with no significant difference in overall survival owing to effective salvage therapy. 6 Locasciulli et al. 22 treated 77 patients with equine ATG, CsA and G-CSF and reported an overall response at 4 months of 55% (17% CR, 38% PR). With a median follow-up of 49 months, the overall response was 62%. 22 Scheinberg et al. 23 reported an overall response of 62% at 6 months with CsA, Cellcept and hATG in 104 patients with AA.
Rabbit anti-thymocyte globulin (rATG) has been used to treat patients with AA refractory to equine ATG. In one study, 30 patients with severe AA (median age 21 years, range 2-67) not responding to a first course of hATG, CsA and G-CSF were given a second course using rATG (3.5 mg/kg per day for 5 days), CsA and G-CSF. No significant side effects were observed and the overall response after 95 days (range 14-377) was 77% with nine patients (30%) achieving CR. The overall survival was 93% and no patients had relapsed at the time of the report. 24 Several studies show equine ATG to be efficacious for a subset of patients with MDS. Molldrem et al. 25 reported on 61 patients Abbreviations: AA, aplastic anemia; MDS, myelodysplastic syndrome. AA group: 1 patient was lost to follow-up and 3 recently received treatment, so 13 patients were evaluable to assess a response (complete, partial or hematologic improvement). MDS group: 12 patients were evaluable for response (CR, PR, HI) as 2 patients with MDS died on treatment, and 1 was too early in treatment course.
Immunosuppressive therapy for bone marrow failure R Garg et al with transfusion-dependent MDS who were treated with equine ATG and prednisone. At 8 months, 21 of 61 patients (34%) no longer required red blood cell transfusions and transfusion independence was maintained in 81% of responders. Of 21 patients, 10 (47.5%) with severe thrombocytopenia had a sustained platelet increase. The median TTR was 55 days with response duration of 10 months. The Kaplan-Meier projection of overall survival was 84% at 38 months. 25 Stadler et al. 26 showed that rATG was equally efficacious and as safe as equine ATG in MDS patients. This multicenter, prospective study administered hATG or rATG with methylprednisolone in 35 patients with MDS. Twenty patients received hATG whereas fifteen received rATG. Four patients had a CR whereas six had a good response defined as a significant rise in blood count or transfusion independence. There was no significant difference between the two treatment arms in clinically relevant responses, overall survival or adverse effects. 26 A Swedish multicenter study evaluated treatment in 20 patients with MDS with rATG and CsA. 27 The overall response rate was 6/20 (30%) and three of the six responders had a CR. This is the first study that has demonstrated that treatment with rATG, CsA and G-CSF can be an effective frontline therapy for patients with AA. The majority of patients with AA (92%) had a response compared to 33% of patients with MDS. This compares favorably to prior studies with hATG and CsA. Furthermore, TTR and median response duration are similar to historical reports. Grade III/IV toxicities were cytopenias, neutropenic fever, renal failure and electrolyte deficiency; however, these side effects were reversible and overall the regimen was safe with no treatment discontinuation because of side effects. We conclude that combination of rATG, CsA and G-CSF can be considered for frontline therapy of AA where the availability of hATG is limited. Our high response rate compares favorably to historical reports using hATG. However, no conclusions regarding the superiority of one or the other product due to the small number of patients treated. We also further demonstrated that a subset of patients with MDS respond to IST. Further studies are needed to establish whether rATG is superior to hATG in first-line therapy of AA and to better delineate what can predict response to IST in both AA and MDS. 
